Related by context. Frequent words. (Click for all words.) 74 refractory chronic lymphocytic 71 R sorafenib tablets 70 imatinib mesylate 70 castrate resistant prostate cancer 70 metastatic castration resistant 69 EGFR expressing metastatic colorectal 69 Epratuzumab 68 EGFR expressing mCRC 68 lung pancreatic 68 non squamous 68 Voreloxin 68 multi kinase inhibitor 67 relapsed refractory multiple myeloma 67 Receives Orphan Drug Designation 67 cutaneous T cell 67 Myelofibrosis 67 metastatic castrate resistant 67 Irinotecan 67 Initiates Phase II 67 metastatic renal cell carcinoma 67 HER2 positive metastatic breast 67 Amrubicin 67 lymphoma CTCL 67 relapsed multiple myeloma 67 trabectedin 67 ThermoDox R 66 multiple myeloma MM 66 Daclizumab 66 gastrointestinal stromal tumors GIST 66 liposomal formulation 66 gastrointestinal stromal tumors 66 leukemia CLL 66 Lubiprostone 66 sunitinib malate 66 proteasome inhibitor 66 superficial bladder cancer 66 CD# expressing 66 Nexavar ® 65 Lenalidomide 65 forodesine 65 Chronic Lymphocytic Leukemia 65 HGS ETR2 65 hepatitis C HCV 65 Initiate Phase 65 KRN# 65 Traficet EN 65 Epidermal Growth Factor Receptor 65 Renal Cell Carcinoma 65 hepatitis B HBV 65 relapsing multiple sclerosis 65 Meets Primary Endpoint 65 tigecycline 65 Panzem R 64 mRCC 64 Presents Positive 64 acute promyelocytic leukemia APL 64 refractory Hodgkin lymphoma 64 Pirfenidone 64 Genasense ® 64 Pralatrexate 64 gets USFDA nod 64 Clevudine 64 Clofarabine 64 oropharyngeal candidiasis 64 metastatic hormone refractory 64 Alemtuzumab 64 luteinizing hormone releasing 64 mTOR inhibitor 64 Pivotal Phase III 64 Belimumab 64 Carfilzomib 64 unresectable 64 post herpetic neuralgia PHN 64 ongoing Phase 1b 64 targeting CD# 64 Copegus R 64 lung ovarian 64 androgen independent 64 refractory multiple myeloma 64 Talactoferrin 64 AEG# 64 Completes Enrollment 64 Eculizumab 64 Chronic Hepatitis C 64 Denufosol 63 resistant ovarian cancer 63 Gefitinib 63 ixabepilone 63 non squamous NSCLC 63 NEBIDO R 63 interferon alfa 2b 63 Zolinza 63 Ixempra 63 hepatocellular carcinoma HCC 63 refractory peripheral T 63 pertuzumab 63 metastatic RCC 63 Application MAA 63 transcriptase inhibitor NNRTI 63 Pegasys ® 63 receiving VELCADE